BACKGROUND: Approximately 25% of thyroid nodule fine-needle aspirates (FNAs) have cytology that is indeterminate for malignant disease. Accurate risk stratification of these FNAs with ancillary testing would reduce unnecessary thyroid surgery. METHODS: We evaluated the performance of an ancillary multiplatform test (MPTX) that has three diagnostic categories (negative, moderate, and positive). MPTX includes the combination of a mutation panel (ThyGeNEXT®) and a microRNA risk classifier (ThyraMIR®). A blinded, multicenter study was performed using consensus histopathology diagnosis among three pathologists to validate test performance. RESULTS: Unanimous consensus diagnosis was reached in 197 subjects with indeterminate thyroid nodules; 36% had disease. MPTX had 95% sensitivity (95% CI,86%-99%) and 90% specificity (95% CI,84%-95%) for disease in prevalence adjusted nodules with Bethesda III and IV cytology. Negative MPTX results ruledout disease with 97% negative predictive value (NPV; 95% CI,91%-99%) at a 30% disease prevalence, while positive MPTX results ruledin high risk disease with 75% positive predictive value (PPV; 95% CI,60%-86%). Such results are expected in four out of five Bethesda III and IV nodules tested, including RAS positive nodules in which the microRNA classifier was useful in rulingin disease. 90% of mutation panel false positives were due to analytically verified RAS mutations detected in benign adenomas. Moderate MPTX results had a moderate rate of disease (39%, 95% CI,23%-54%), primarily due to RAS mutations, wherein the possibility of disease could not be excluded. CONCLUSIONS: Our results emphasize that decisions for surgery should not solely be based on RAS or RAS-like mutations. MPTX informs management decisions while accounting for these challenges.
BACKGROUND: Approximately 25% of thyroid nodule fine-needle aspirates (FNAs) have cytology that is indeterminate for malignant disease. Accurate risk stratification of these FNAs with ancillary testing would reduce unnecessary thyroid surgery. METHODS: We evaluated the performance of an ancillary multiplatform test (MPTX) that has three diagnostic categories (negative, moderate, and positive). MPTX includes the combination of a mutation panel (ThyGeNEXT®) and a microRNA risk classifier (ThyraMIR®). A blinded, multicenter study was performed using consensus histopathology diagnosis among three pathologists to validate test performance. RESULTS: Unanimous consensus diagnosis was reached in 197 subjects with indeterminate thyroid nodules; 36% had disease. MPTX had 95% sensitivity (95% CI,86%-99%) and 90% specificity (95% CI,84%-95%) for disease in prevalence adjusted nodules with Bethesda III and IV cytology. Negative MPTX results ruledout disease with 97% negative predictive value (NPV; 95% CI,91%-99%) at a 30% disease prevalence, while positive MPTX results ruledin high risk disease with 75% positive predictive value (PPV; 95% CI,60%-86%). Such results are expected in four out of five Bethesda III and IV nodules tested, including RAS positive nodules in which the microRNA classifier was useful in rulingin disease. 90% of mutation panel false positives were due to analytically verified RAS mutations detected in benign adenomas. Moderate MPTX results had a moderate rate of disease (39%, 95% CI,23%-54%), primarily due to RAS mutations, wherein the possibility of disease could not be excluded. CONCLUSIONS: Our results emphasize that decisions for surgery should not solely be based on RAS or RAS-like mutations. MPTX informs management decisions while accounting for these challenges.
Authors: Tarik M Elsheikh; Sylvia L Asa; John K C Chan; Ronald A DeLellis; Clara S Heffess; Virginia A LiVolsi; Bruce M Wenig Journal: Am J Clin Pathol Date: 2008-11 Impact factor: 2.493
Authors: Kepal N Patel; Trevor E Angell; Joshua Babiarz; Neil M Barth; Thomas Blevins; Quan-Yang Duh; Ronald A Ghossein; R Mack Harrell; Jing Huang; Giulia C Kennedy; Su Yeon Kim; Richard T Kloos; Virginia A LiVolsi; Gregory W Randolph; Peter M Sadow; Michael H Shanik; Julie A Sosa; S Thomas Traweek; P Sean Walsh; Duncan Whitney; Michael W Yeh; Paul W Ladenson Journal: JAMA Surg Date: 2018-09-01 Impact factor: 14.766
Authors: Yuri E Nikiforov; N Paul Ohori; Steven P Hodak; Sally E Carty; Shane O LeBeau; Robert L Ferris; Linwah Yip; Raja R Seethala; Mitchell E Tublin; Michael T Stang; Christopher Coyne; Jonas T Johnson; Andrew F Stewart; Marina N Nikiforova Journal: J Clin Endocrinol Metab Date: 2011-08-31 Impact factor: 5.958
Authors: Iñigo Landa; Ian Ganly; Timothy A Chan; Norisato Mitsutake; Michiko Matsuse; Tihana Ibrahimpasic; Ronald A Ghossein; James A Fagin Journal: J Clin Endocrinol Metab Date: 2013-07-05 Impact factor: 5.958
Authors: J Woody Sistrunk; Alexander Shifrin; Marc Frager; Ricardo H Bardales; Johnson Thomas; Norman Fishman; Philip Goldberg; Richard Guttler; Edward Grant Journal: J Am Soc Cytopathol Date: 2020-03-10
Authors: Andrea R Marcadis; Pablo Valderrabano; Allen S Ho; Justin Tepe; Christina E Swartzwelder; Serena Byrd; Wendy L Sacks; Brian R Untch; Ashok R Shaha; Bin Xu; Oscar Lin; Ronald A Ghossein; Richard J Wong; Jennifer L Marti; Luc G T Morris Journal: Surgery Date: 2018-10-22 Impact factor: 3.982
Authors: David L Steward; Sally E Carty; Rebecca S Sippel; Samantha Peiling Yang; Julie A Sosa; Jennifer A Sipos; James J Figge; Susan Mandel; Bryan R Haugen; Kenneth D Burman; Zubair W Baloch; Ricardo V Lloyd; Raja R Seethala; William E Gooding; Simion I Chiosea; Cristiane Gomes-Lima; Robert L Ferris; Jessica M Folek; Raheela A Khawaja; Priya Kundra; Kwok Seng Loh; Carrie B Marshall; Sarah Mayson; Kelly L McCoy; Min En Nga; Kee Yuan Ngiam; Marina N Nikiforova; Jennifer L Poehls; Matthew D Ringel; Huaitao Yang; Linwah Yip; Yuri E Nikiforov Journal: JAMA Oncol Date: 2019-02-01 Impact factor: 31.777
Authors: Miguel Melo; Adriana Gaspar da Rocha; João Vinagre; Rui Batista; Joana Peixoto; Catarina Tavares; Ricardo Celestino; Ana Almeida; Catarina Salgado; Catarina Eloy; Patrícia Castro; Hugo Prazeres; Jorge Lima; Teresina Amaro; Cláudia Lobo; Maria João Martins; Margarida Moura; Branca Cavaco; Valeriano Leite; José Manuel Cameselle-Teijeiro; Francisco Carrilho; Manuela Carvalheiro; Valdemar Máximo; Manuel Sobrinho-Simões; Paula Soares Journal: J Clin Endocrinol Metab Date: 2014-01-29 Impact factor: 5.958
Authors: Nicole A Cipriani; Daniel N Johnson; David H Sarne; Peter Angelos; Ward Reeves; Tatjana Antic Journal: Endocr Pathol Date: 2022-10-13 Impact factor: 4.056
Authors: Xavier M Keutgen; Hui Li; Kelvin Memeh; Julian Conn Busch; Jelani Williams; Li Lan; David Sarne; Brendan Finnerty; Peter Angelos; Thomas J Fahey; Maryellen L Giger Journal: J Med Imaging (Bellingham) Date: 2022-05-26
Authors: Mark A Lupo; Ann E Walts; J Woody Sistrunk; Thomas J Giordano; Peter M Sadow; Nicole Massoll; Ryan Campbell; Sara A Jackson; Nicole Toney; Christina M Narick; Gyanendra Kumar; Alidad Mireskandari; Sydney D Finkelstein; Shikha Bose Journal: Diagn Cytopathol Date: 2020-08-07 Impact factor: 1.582